Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
نویسندگان
چکیده
Dna2 was first characterized in yeast as an essential gene encoding a protein with both helicase and endonuclease activities involved in maturation of Okazaki fragments during DNA replication. Dna2 also plays a role in double-strand break (DSB) repair by homolo-gous recombination. The respective contributions of its replication and/or repair functions toward cell viability and resistance to geno-toxic stress is not entirely clear. Recent studies, including that of Karanja et al. 1 in a recent issue of Cell Cycle, are starting to clarify the multifac-eted roles of DNA2. Together with the endonuclease Rad27 (Fen1 in higher eukaryotes), Dna2 removes 5' flaps generated by strand displacement during synthesis by Pol δ on the lagging strand. Most 5' flap processing during replication is due to the activity of Rad27, yet Rad27∆ yeast cells are viable, whereas Dna2∆ cells are not. This suggests that the essential role of Dna2 in genome maintenance is distinct from Okazaki fragment maturation. 2 indeed, Dna2 is a target of the intra-S-phase checkpoint in fission yeast and stabilizes replication forks. 3 Dna2 phos-phorylation by Cds1 promotes the association of Dna2 to replication forks to counteract fork reversal. Reversed forks can be erroneously recognized as recombination intermedi-ates leading genomic rearrangements. 4 Thus, Dna2 maintains genome stability by processing stalled forks before they collapse into aberrant structures. Similarly, Exo1 nuclease also participates in preventing the generation of " chicken-foot " structures from blocked forks, but, interestingly, Exo1 appears to be functional, even in the absence of an active checkpoint. 4 Homology-dependent repair requires the generation of 3' ssDNA, a process called resec-tion that is regulated by CDKs. Resection provides the template that is used by Rad51 recombinase to search for homologous sequences.5 Resection is initiated by the MRN (Mre11-Rad50-Nbs1) complex and its co-factor CtiP. More processive, long-range resection is then performed by two partially overlapping pathways involving Dna2 and/or Exo1. 5 in the November 2012 issue of Cell Cycle, Karanja et al. 1 provide additional evidence for the role of Dna2 and Exo1 in S-phase. Using siRNA-mediated Dna2 and Exo1 knock-down, they show that both nucleases contribute to cell viability following CPT, cisplatin or MMS treatments in a redundant manner. The data further support the conserved roles of Dna2 and Exo1 in the DNA damage response. Notably, the authors observe that Dna2-depleted cells have more profound defects in resection and Chk1 activation than Exo1-depleted cells when treated with cisplatin, a DNA-damaging …
منابع مشابه
Study of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia
Background and Aim: Chronic myeloid leukemia(CML) is a clonal myeloproliferative disease, characterized by BCR/ABL translocation. Using tyrosine kinase inhibitors such as Imatinib, treatment for this disease has progressed remarkably. However, resistance to tyrosine kinase inhibitor is a major obstacle. Signal transducer and activator of transcription 3(STAT3) is an important transcription fact...
متن کاملCoexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملAnalysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملRole of Oxidative Stress in Modulating Unfolded Protein Response Activity in Chronic Myeloid Leukemia Cell Line
Background: Recently, it has been revealed that tyrosine kinase inhibitors (TKIs) act through inducing both oxidative and endoplasmic reticulum (ER) stress in chronic myeloid leukemia cells. However, ER stress signaling triggers both apoptotic and survival processes within cells. Nevertheless, mechanisms by which TKIs avoid the pro-survival effects are not clear. The aim of this study was to ev...
متن کاملTyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
BACKGROUND Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia--regardless of the significant reduction of disease burden during treatment--since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited. DESIGN AND METHODS We studied t...
متن کاملCytogenetic and FMS-Like Tyrosine Kinase 3 Mutation Analyses in Acute Promyelocytic Leukemia Patients
Background: The secondary genetic changes other than the promyelocytic leukemia-retinoic acid receptor (PML-RARA) fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia. However, the prognostic significance of FLT3 mutat...
متن کامل